Page 246 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
©2025 Ferrata Storti Foundation Published under a CC BY-NC license
Disclosures
CP has received honoraria from Neovii Biotech, Jazz Pharmaceuticals and Novartis; performed consulting or advisory roles for Amgen and Neovii Biotech; participated in speakers’ bureau for Medac, Riemser and Amgen; received research funding from Medac, Neovii Biotech, Riemser and Jazz Pharmaceuticals and received travel expenses from Neovii Biotech and Jazz Pharmaceuticals. CR reports personal fees from Amgen, Jazz Pharmaceuticals and Sobi and grants and personal fees from Shire and Medac, outside the submitted work. AvS reports having received personal fees from Amgen, Shire, Jazz Pharmaceuticals, Roche and MorphoSys, outside the submitted work. CL has no conflicts of interest to disclose. FL reports advisory board membership in Amgen, Novartis, Bellicum Pharmaceuticals, Neovii and Vertex and participation in speakers’ bureau for Amgen, Novartis, Miltenyi, Medac, Jazz Pharmaceuticals and Takeda, outside the submitted work. ABru, ABre, YZ and GZ are employed by Amgen and hold stock in the company. GZ reports issue of patents (20190300609, 20130323247 and 20110262440), and has patents pending (10696744,
References
1. Peters C, Dalle JH, Locatelli F, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39(4):295-307.
2. Eichinger A, Poetschger U, Glogova E, et al. Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial. Leukemia. 2022; 36(11):2567-2576.
3. Lawitschka A, Peters C. Long-term effects of myeloablative allogeneic hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia. Curr Oncol Rep. 2018;20(9):74.
4. Saglio F, Zecca M, Pagliara D, et al. Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. Bone Marrow Transplant. 2020;55(10):1918-1927.
5. Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):843-854.
6. Locatelli F, Zugmaier G, Rizzari C, et al. Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. Leukemia. 2023;37(1):222-225.
7. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat
10662243, 20190142846, 20170327581, 10130638, 9688760, 20170122947, 9486475, 20160208001, 9192665, 20150071928, 8840888, 20140228316, 20140227272, 20130287778 and 20130287774).
Contributions
All authors were involved in data generation, data analysis, and review of the manuscript; they read and approved the manuscript and provided consent for its publication.
Funding
The authors acknowledge funding from Amgen Inc. The authors thank Priti Kadu, MSc, and Ravikanth Maraboina, MSc, of IQVIA for support with statistical analyses funded by Amgen Inc. Swapnil Kher, PhD, of Cactus Life Sciences (part of Cactus Communications) provided medical writing assistance funded by Amgen Inc. Graphics support was provided by Bob Dawson of Cactus Communications and funded by Amgen Inc.
Data-sharing statement
Qualified researchers may request data from Amgen clinical studies.
relapsed childhood acute lymphoblastic leukemia. Blood.
2012;120(14):2807-2816.
8. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on
outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376(9757):2009-2017.
9. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
10. Bader P, Kreyenberg H, Henze GHR, et al. Prognostic value of minimal residual disease quantification before allogeneic stem- cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM study group. J Clin Oncol. 2009;27(3):377-384.
11. Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531.
12. Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.
13. Ruggeri A, Michel G, Dalle JH, et al. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis. Leukemia. 2012;26(12):2455-2461.
Haematologica | 110 January 2025
238